PUBLISHER: The Business Research Company | PRODUCT CODE: 1955417
PUBLISHER: The Business Research Company | PRODUCT CODE: 1955417
Head and neck cancer therapeutics encompass the range of treatment strategies and options used to manage and treat cancers of the head and neck region. These therapeutics can benefit from advanced approaches such as the precision offered by intensity-modulated proton therapy. Treatment also includes effective modalities such as surgery, radiation therapy, chemotherapy, specific medications, and immunotherapy.
The main types of head and neck cancer therapeutics include programmed cell death (PD) inhibitors, microtubule inhibitors, and epidermal growth factor receptor (EGFR) inhibitors. Programmed cell death (PD) inhibitors are a class of drugs known as programmed cell death protein 1 (PD-1) inhibitors that function by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are proteins expressed on certain cancer cells. These drugs are administered through injectable and oral routes and are distributed via channels such as retail and specialty pharmacies, hospital pharmacies, and online pharmacies. They are applied across treatment approaches including surgery, radiation therapy, chemotherapy, immunotherapy, and others.
Tariffs have affected the head and neck cancer therapeutics market by increasing the cost of imported medical equipment, advanced proton therapy systems, and specialized pharmaceuticals. This has impacted segments such as intensity-modulated proton therapy, injectable medications, and high-precision surgical tools, particularly in regions reliant on imports like North America and Europe. While tariffs have raised production and treatment costs, they have also encouraged local manufacturing, innovation, and development of cost-effective therapies, offering potential long-term benefits to the market.
The head and neck cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides head and neck cancer therapeutics market statistics, including head and neck cancer therapeutics industry global market size, regional shares, competitors with a head and neck cancer therapeutics market share, detailed head and neck cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the head and neck cancer therapeutics industry. This head and neck cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The head and neck cancer therapeutics market size has grown rapidly in recent years. It will grow from $1.88 billion in 2025 to $2.07 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to rising prevalence of head and neck cancers, limited availability of targeted therapies, adoption of conventional chemotherapy and radiation, increasing awareness of early diagnosis, growth of hospital-based treatment centers.
The head and neck cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $3.13 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to development of targeted immunotherapies, integration of ai-powered diagnostics, expansion of outpatient and precision treatment centers, rising investment in biotechnology research, adoption of personalized medicine approaches. Major trends in the forecast period include precision proton therapy adoption, immunotherapy expansion, multimodal treatment approaches, minimally invasive surgical techniques, personalized medicine integration.
The rising prevalence of head and neck cancer is anticipated to drive the expansion of the head and neck cancer therapeutics market in the coming years. Head and neck cancer is a disease characterized by the uncontrolled growth of abnormal cells in the tissues of the head and neck region. An increase in the number of cases heightens the demand for improved diagnostic tools and effective treatment options to address genetic mutations and cancer cell abnormalities. For example, in 2023, according to Cancer Research UK, a UK-based independent cancer research organization, the incidence of head and neck cancer in the UK is expected to rise by 3% between 2023 and 2025, while deaths related to head and neck cancers are projected to increase by 12% during the same period. Consequently, the growing prevalence of head and neck cancer is contributing to the growth of the head and neck cancer therapeutics market.
Major companies operating in the head and neck cancer therapeutics market are focusing on the introduction of new drug-based treatments to improve outcomes for affected patients. Drug treatment involves the use of pharmaceutical agents to manage, treat, or alleviate diseases and related symptoms. For instance, in October 2023, Coherus BioSciences Inc., a US-based biopharmaceutical company, announced approval from the U.S. Food and Drug Administration for its drug Loqtorzi, also known as toripalimab-tpzi. The approval was granted for use of the drug in combination with cisplatin and gemcitabine as first-line therapy for adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma. Clinical trial results showed that adverse reactions occurred in fewer than 20% of patients, both when used as an initial treatment and when administered as monotherapy.
In March 2023, InvoX Pharma Ltd., a UK-based biopharmaceutical company, acquired F-star Therapeutics Inc. for approximately $161 million. This acquisition strengthened InvoX Pharma's oncology therapeutics portfolio and expanded its reach in cancer immunotherapy. F-star Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company focused on developing immunotherapeutic treatments for head and neck cancers.
Major companies operating in the head and neck cancer therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi Aventis LLC, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Incyte Corporation, Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Ligand Pharmaceuticals, Acceleron Pharma Inc., Taiho Pharmaceutical Co. Ltd., AB Science SA
North America was the largest region in the head and neck cancer therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the head and neck cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The head and neck cancer therapeutics market consists of sales of bleomycin sulfate, cetuximab, docetaxel, and erbitux. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Head And Neck Cancer Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses head and neck cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for head and neck cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The head and neck cancer therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.